Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint

Live updates

1. 1h ago

   Otsuka and Ionis move ulefnersen toward FDA approval after Phase 3 success

   Otsuka is preparing an FDA submission for ulefnersen following positive topline results from the Phase 3 FUSION study. The drug met its primary endpoint and demonstrated a favorable safety and tolerability profile. Developed in partnership with Ionis Pharmaceuticals, ulefnersen is positioned as the first potential disease modifying treatment for FUS-ALS. To provide immediate options for patients, Otsuka has established an Early Access Program for eligible individuals living with FUS-ALS while the formal regulatory process proceeds.

   Why it matters

   FUS-ALS is a specific form of amyotrophic lateral sclerosis. This development represents a shift toward targeted therapies for genetic subtypes of the disease. Regulatory approval would mark a significant milestone in treating a condition that currently lacks disease modifying options.

   What is confirmed

   • Ulefnersen met its primary endpoint in the Phase 3 FUSION study.
   • Otsuka and Ionis Pharmaceuticals partnered to develop the drug.
   • Ionis reported that ulefnersen has a favorable safety and tolerability profile.
   • Otsuka created an Early Access Program for eligible people with FUS-ALS.

   What to watch next

   • FDA decision on the ulefnersen application
   • Full publication of the FUSION study data
   Sources used for this update (6)

   1. Endpoints News — Amgen’s Phase 3 Sjögren’s win; Novartis’ $900M radioligand deal
   2. Fierce Biotech — Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
   3. Yahoo Finance — Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
   4. TradingView — Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
   5. BioSpace — Otsuka Establishes Ulefnersen Early Access Program (EAP) for Eligible People Living with FUS-ALS
   6. Yahoo — Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen
   confidence 100%